Table 2.

Main clinical manifestations and outcomes reported in studies of vertical transmission by CHIKV.

Reference/Country	Number of neonates	Gender	Clinical manifestation	Treatment	Outcome
Sahana M. Srinivas, G.C. Marlursiddappa Pradeep, 2018. India14	1	Male	11 days old fever, poor feeding, presumed sepsis, hyperpigmented macules on face and trunk, multiple small necrotic ulcers	Supportive measures and physiotherapy	Extensive dystrophic calcifications, atrophic scars and no deformities
Shen et al., 2021 China and Myanmar15	3	2 males and 1 female	Disseminated maculopapular rash, fever, drowsiness, arthralgia	Antibiotics, antypretic. The female baby received antiviral treatment (IFNB-1a 800,000 IU bid)	They progressed favorably and was discharged asymptomatic
Fajardo et al., 2021. Brazil16	2	Females	No symptoms in the first weeks of life. Developmental delay observed from 83 days of life.	Clinical monitoring of neurodevelopment	Neurocognitive delay up to 3 years of age
Sreekanth et al., 2022. India17	1	Female	Six-day old late onset sepsis, seizures, cranial hemorrhage, maculopapular rash, perioral hyperpigmenation	Phenobarbital, fresh frozen plasma, red blood cell transfusion, IVIG 1 g/Kg on the 7th and 9th days of admission	On follow up at three months, neurological examination was normal
Faustino et al., 2022. Brazil18	33	57.6 % male	Fever (79 %), myalgia (100 %), arthralgia (100 %) One presented neurodevelopment delay and one presented pos natal sepsis	Not described	At 3-months only one child presented neurological alterations
Torres et al., 2022. Brazil19	3	3 females	Fever, jaundice, thrombocytopenia, apnea, seizures, maculopapular rash	Antibiotics	One baby evolved with altered brain image on magnetic resonance
Sagay, et al. 2024. Nigeria20	26	Not described	Not described	Not described	Three stillbirths, two multiple congenital anomalies, one polydactyly with sepsis and jaundice, and one preterm